|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | A61K 48/00 | (2006.01) |
| A61K 39/00 | (2006.01) | ||
| A61K 31/7105 | (2006.01) | ||
| A61K 9/16 | (2006.01) |
| (11) | Number of the document | 4023249 |
| (13) | Kind of document | T |
| (96) | European patent application number | 21195046.4 |
| Date of filing the European patent application | 2015-04-23 | |
| (97) | Date of publication of the European application | 2022-07-06 |
| (45) | Date of publication and mention of the grant of the patent | 2024-10-09 |
| (46) | Date of publication of the claims translation | 2025-01-10 |
| (30) | Number | Date | Country code |
| 201461983250 P | 2014-04-23 | US | |
| 201462088994 P | 2014-12-08 | US |
| (72) |
CIARAMELLA, Giuseppe , US
BOUCHON, Axel , DE
HUANG, Eric, Yi-Chen , US
|
| (73) |
ModernaTX, Inc. ,
325 Binney Street, Cambridge, MA 02142,
US
|
| (74) |
Reda ŽABOLIENĖ,
METIDA, Verslo centras "VERTAS", Gynėjų g. 16, LT-01109 Vilnius,
LT
|
| (54) | Nuleorūgšties vakcinos |
| NUCLEIC ACID VACCINES |
| Payment date | Validity (years) | Amount | |
| 2025-03-19 | 11 | 289.00 EUR |
| 2026-04-23 |